Clinical Trials

Be sure to visit the University of Michigan’s main gateway to clinical research trials:

Engage http://www.umengage.org/

There you can find trials actively recruiting at U of M and general information about research and how to participate.

For specific information on HIV research you can also speak with your medical provider at your next appointment or research personnel at 734-647-9830

Current Research

See the Engage website for recruitment specifics

Molecular Mechanisms of HIV Disease Pathogenesis I

Sponsor: National Institutes of Health

Goal: On therapy viral load decreases, but once stopped viral load becomes high again. Where is the virus waiting in the body when is it “undetectable” in the blood? This study suggests it may be bone marrow.

Process: A sample of bone marrow is taken from the hip. Requires a 1 hour visit in the hospital for the procedure.

IMPACT: I50L mutation on a failed Reyataz (atazanavir) regimen

Sponsor: Bristol-Myers Squibb

Goal: Therapy can become ineffective due to the development of resistance when the virus mutates to get around the drug. Tests like a genotype can detect these mutations and provide your doctor information for a better regimen for you. This study suggests one specific mutation called the I50L substitution occurs with Reyataz, and seeks to better understand treatment options.

Process: A blood sample is taken to test. Requires 1 blood draw in Taubman Center.

Recently Closed Research

TMC125-C214 Early Access Program

Sponsor: Tibotec Pharmaceuticals

Update: TMC125 is now Intelence (etravirine). FDA approved Jan 18, 2008.

SMART: Strategies for Management of Anti-Retroviral Therapy

Sponsor: Division of AIDS, National Institute of Allergy and Infectious Diseases

Update: The SMART study was discontinued July, 2007

MOTIVATE: UK-427,857 Study

Sponsor: Pfizer, Inc.

Update: UK-427,857 is now Selzentry (maraviroc). FDA approved August 6, 2007